<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="6775">5-Aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) may protect against the development of <z:mp ids='MP_0001845'>inflammation</z:mp>-associated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In vitro data suggest that, in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, <z:chebi fb="0" ids="6775">5-ASA</z:chebi> induces cell cycle arrest, but the molecular mechanism leading to this arrest remains to be determined </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To dissect the signal transduction events that lead to <z:chebi fb="0" ids="6775">5-ASA</z:chebi> mediated inhibition of proliferation of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, focusing on mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR), a regulator of cell cycle progression </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The influence of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> on mTOR signalling was examined in a panel of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> on the pathways that control mTOR activity were studied in detail in two different <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines, using western blot, siRNA, a phospholipase D (PLD) activity assay, proliferation assays and cell cycle analysis </plain></SENT>
<SENT sid="5" pm="."><plain>The phosphorylation status of mTOR and its downstream target, ribosomal protein S6, was studied in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> before and after topical <z:chebi fb="0" ids="6775">5-ASA</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with <z:chebi fb="0" ids="6775">5-ASA</z:chebi> inhibited mTOR signalling in vitro and in vivo </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6775">5-ASA</z:chebi> had no effect on any of the pathways that regulate the activity of the tuberous <z:mp ids='MP_0000612'>sclerosis</z:mp> complex in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Both proliferation and mTOR activity depended on PLD, an enzyme that generates <z:chebi fb="0" ids="16337">phosphatidic acid</z:chebi> (PA) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6775">5-ASA</z:chebi> treatment inhibited PLD activity and proliferation; these effects could be rescued with exogenous PA </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="6775">5-ASA</z:chebi> interferes with proliferation of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells via inhibition of PLD-dependent generation of PA and loss of mTOR signalling </plain></SENT>
</text></document>